Milton Lönnroth

Co-Founder and CEO, Atley Solutions

An Introduction to the Atley C100

ABSTRACT

The Atley C100 is the world’s first and only commercial manufacturing system specifically designed for At-211 radiopharmaceuticals. This state-of-the-art platform addresses the critical challenges of At-211 radiopharmaceutical manufacturing, enabling reliable and scalable production from non-clinical R&D to full-scale commercial rollout.

Purification process:
Starting with an irradiated Bi-209 target, the Atley C100 efficiently purifies At-211 through a cutting-edge dry distillation process. The final elution step of the purification is highly flexible, allowing the use of different solvents to suit specific downstream radiochemistry processes. This purification process is completed in less than 30 minutes and achieves a non-decay-corrected yield of minimum 80%. The resulting At-211 solution contains minimal impurities, ensuring exceptional quality for subsequent synthesis steps.

Radiopharmaceutical synthesis & purification:
Automated radiolabeling in the Atley C100 uses a peristaltic pump and 3×5 valves to precisely dose reagents into a reactor vial. The reactor can be actively heated and agitated for optimal synthesis conditions. A position for a purification column equipped with an in-line radiodetector ensures final purification of the radiolabeled compound. The fully disposable fluid pathway enhances regulatory compliance and allows for a seamless transition from non-clinical to clinical manufacturing. Atley Solutions supplies all necessary consumables for use with the Atley C100.

SPEAKER BIO

Milton Lönnroth is the Co-Founder and CEO of Atley Solutions. He holds a First-Class Honours Bachelor’s degree in Biochemical Engineering from University College London and has studied Knowledge-Based Entrepreneurship at the School of Business, Economics and Law at the University of Gothenburg.

As the company’s first employee, Milton has guided Atley Solutions from its inception to becoming a global leader in enabling technologies for At-211 radiopharmaceuticals.

Return to conference agenda